Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma

Waleed Alduaij; Tim M. Illidge

doi:10.1007/s11912-009-0049-8

Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma

Research output: Contribution to journal › Article › peer-review

Abstract

The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Earlyphase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients. © Current Medicine Group, LLC 2009.

Original language	English
Pages (from-to)	363-370
Number of pages	7
Journal	Current Oncology Reports
Volume	11
Issue number	5
DOIs	https://doi.org/10.1007/s11912-009-0049-8
Publication status	Published - 2009

Access to Document

10.1007/s11912-009-0049-8

Cite this

@article{6cb9f281f5524aecb8889bdb43e28f59,

title = "Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma",

abstract = "The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Earlyphase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients. {\textcopyright} Current Medicine Group, LLC 2009.",

author = "Waleed Alduaij and Illidge, {Tim M.}",

year = "2009",

doi = "10.1007/s11912-009-0049-8",

language = "English",

volume = "11",

pages = "363--370",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Current Science, Inc",

number = "5",

}

TY - JOUR

T1 - Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma

AU - Alduaij, Waleed

AU - Illidge, Tim M.

PY - 2009

Y1 - 2009

N2 - The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Earlyphase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients. © Current Medicine Group, LLC 2009.

AB - The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Earlyphase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients. © Current Medicine Group, LLC 2009.

U2 - 10.1007/s11912-009-0049-8

DO - 10.1007/s11912-009-0049-8

M3 - Article

C2 - 19679011

VL - 11

SP - 363

EP - 370

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -

Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma

Abstract

Access to Document

Fingerprint

Cite this